URGN
UroGen Pharma Ltd
41.40$
+2.1%
vs. previous close
Closing price · As of: Oct 2, 2026
Statements
Cash Flow
All figures as a percentage of revenue in the same period.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -83.0% | -55.5% | -169.0% | -108.7% | -109.8% | -55.4% | -207.5% | -164.5% | -153.8% | -101.3% | -88.9% | -45.6% | -84.2% | |
| 2.0% | 1.8% | 1.9% | 1.2% | 1.1% | 1.2% | 2.5% | 2.5% | 2.3% | 1.8% | 1.3% | 0.9% | 1.4% | |
| 10.7% | 11.1% | 14.7% | 16.3% | 13.8% | 13.4% | 15.2% | 11.3% | 11.0% | 8.3% | 9.1% | 7.4% | 8.5% | |
| -5.1% | 28.0% | -21.4% | 11.7% | -36.2% | 63.1% | -12.8% | 21.6% | -49.1% | -48.3% | -59.0% | -33.9% | -45.8% | |
| 0.5% | 0.2% | 0.3% | 0.4% | 0.4% | 0.5% | 0.2% | 0.6% | 0.3% | 0.0% | 0.1% | 0.1% | 0.1% | |
| 1.9% | -48.2% | 72.0% | 54.9% | -423.5% | 246.8% | -128.2% | 117.3% | 114.2% | 73.3% | -40.6% | 2.3% | 21.2% | |
| – | – | – | – | – | 0.0% | 0.0% | 0.0% | 0.0% | -4.9% | 127.6% | -0.5% | 33.3% | |
| 556.7% | 0.2% | 291.0% | 459.0% | 157.1% | 0.3% | 0.2% | 1.2% | 30.1% | 82.8% | 128.0% | 0.7% | 55.8% | |
| 475.6% | -103.3% | 194.0% | 405.2% | -376.2% | 191.6% | -335.5% | -45.9% | -9.5% | 54.7% | -1.6% | -42.6% | -7.2% | |
| -83.4% | -55.7% | -169.0% | -109.1% | -110.1% | -55.9% | -207.7% | -165.0% | -154.1% | -101.3% | -89.0% | -45.6% | -84.3% |
LTM = last twelve months (sum of the four most recent quarters).
Data as of: October 2, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.